What are the pathophysiology, etiology, clinical signs and symptoms of acute bronchiolitis in infants, and how is it managed in an outpatient clinic setting?

Acute Bronchiolitis in Infants: Pathophysiology, Etiology, Clinical Presentation, and Outpatient Management

Pathophysiology

Acute bronchiolitis is characterized by acute inflammation, edema, and necrosis of epithelial cells lining the small airways, accompanied by increased mucus production and bronchospasm 1. This inflammatory cascade results in airway obstruction that manifests as the characteristic clinical syndrome seen in affected infants.

Etiology

Respiratory syncytial virus (RSV) is the predominant causative agent, with peak incidence occurring between December and March 1. However, bronchiolitis represents a clinical syndrome caused by multiple viral pathogens including:

• RSV (most common - 90% of children infected in first 2 years of life)
• Human metapneumovirus
• Influenza virus
• Adenovirus
• Parainfluenza virus
• Rhinovirus
• Coronavirus 1

Up to 40% of RSV-infected children will develop lower respiratory tract infection 1. Importantly, RSV infection does not confer long-term immunity, and reinfections occur throughout life 1.

Clinical Signs and Symptoms

The diagnosis is purely clinical based on history and physical examination - no laboratory or radiologic studies are needed routinely 1.

Typical Presentation:

• Viral upper respiratory prodrome (rhinitis, rhinorrhea)
• Tachypnea (respiratory rate varies by age: 50th percentile is 41 breaths/min at 0-3 months, decreasing to 31 at 12-18 months)
• Wheezing and/or crackles on auscultation
• Cough
• Increased respiratory effort: nasal flaring, grunting, intercostal/subcostal retractions
• Use of accessory muscles 1, 2

Critical Assessment Points:

Evaluate for risk factors for severe disease that warrant closer monitoring or hospitalization 1, 2:

• Age < 12 weeks
• History of prematurity (< 35 weeks gestation)
• Underlying cardiopulmonary disease (congenital heart disease, bronchopulmonary dysplasia)
• Immunodeficiency
• In utero smoke exposure

Assess impact on:

• Mental status
• Feeding ability
• Hydration status
• Family's ability to provide care and return for follow-up 2

---

Outpatient Clinic Management

Diagnostic Approach

Make the diagnosis clinically without ordering routine laboratory tests or chest radiographs 1. The presence of viral upper respiratory symptoms followed by tachypnea, wheezing, and increased work of breathing in an infant < 2 years old during winter months is sufficient for diagnosis.

Treatment Algorithm for OPD Setting

1. Supportive Care is the ONLY Evidence-Based Treatment

Do NOT routinely use the following medications - they do not improve clinical outcomes and may cause harm 1:

• ❌ Bronchodilators (albuterol/salbutamol) - not recommended routinely 1

  • Exception: A carefully monitored trial may be attempted with objective assessment (e.g., respiratory rate, work of breathing). Continue ONLY if documented positive clinical response occurs 1

• ❌ Corticosteroids - should NOT be used routinely 1

• ❌ Antibiotics - use ONLY if specific evidence of bacterial co-infection exists (treat the bacterial infection as you would in absence of bronchiolitis) 1

• ❌ Ribavirin - not recommended 1

• ❌ Chest physiotherapy - not recommended 1

2. Hydration Assessment and Management

Assess hydration status and ability to take oral fluids - this is a STRONG recommendation 1.

• If infant is feeding adequately and well-hydrated → manage at home with close follow-up
• If unable to maintain adequate oral intake → consider hospitalization for IV/NG hydration

3. Oxygen Assessment

Measure oxygen saturation (SpO₂) 1:

• SpO₂ persistently < 90% → supplemental oxygen indicated; consider hospitalization
• SpO₂ ≥ 90% with good feeding and minimal respiratory distress → may manage outpatient with close follow-up
• Oxygen can be discontinued when SpO₂ ≥ 90%, infant feeds well, and has minimal respiratory distress 1

Important caveat: Infants with hemodynamically significant heart disease, chronic lung disease, or prematurity require closer monitoring during oxygen weaning 1.

4. Disposition Decision-Making

Discharge home if:

• SpO₂ ≥ 90% on room air
• Adequate oral intake maintained
• Minimal to mild respiratory distress
• No high-risk features (age < 12 weeks, prematurity, cardiopulmonary disease, immunodeficiency)
• Family able to provide care and return if worsening 1, 2

Consider hospitalization if:

• SpO₂ persistently < 90%
• Unable to maintain hydration
• Significant respiratory distress (severe retractions, grunting, apnea)
• Age < 12 weeks (especially < 3 months)
• High-risk underlying conditions
• Unreliable follow-up or family unable to care for infant 1, 2

5. Parent Education

Counsel families on 1:

• Avoid passive smoke exposure (strong recommendation)
• Hand hygiene to prevent transmission
• Expected disease course: Most infants are cough-free by day 21 (mean resolution 8-15 days) 3
• Return precautions: worsening work of breathing, decreased feeding, lethargy, apnea
• Breastfeeding is recommended to decrease risk of lower respiratory tract disease 1

---

Common Pitfalls to Avoid

1. Over-testing: Routine chest X-rays and viral testing do not change management and increase costs 1

2. Inappropriate medication use: Despite guidelines, bronchodilators and steroids remain widely prescribed but lack efficacy 4, 5. While some recent meta-analyses suggest potential benefits in select outpatient populations 4, the highest quality guideline evidence from AAP strongly recommends against routine use 1

3. Continuous pulse oximetry: Not routinely needed as clinical course improves; can lead to unnecessary interventions for transient desaturations 1

4. Misdiagnosing asthma: Bronchiolitis is a distinct entity. Do not use asthma medications unless other evidence of asthma is present (recurrent wheeze, dyspnea beyond acute episode) 3

5. Inadequate risk stratification: Always assess for high-risk features that warrant closer monitoring or lower threshold for admission 1, 2

---

Chronic Cough Post-Bronchiolitis (> 4 weeks)

If cough persists beyond 4 weeks, manage according to pediatric chronic cough guidelines 3:

• Evaluate for specific cough pointers
• For wet/productive cough without specific pointers: consider 2-week trial of antibiotics targeting common respiratory bacteria (S. pneumoniae, H. influenzae, M. catarrhalis)
• Do NOT use asthma medications unless other asthma evidence present
• Do NOT use inhaled osmotic agents 3

---

Prevention

Palivizumab prophylaxis may be administered to high-risk infants 1:

• Infants with prematurity (< 35 weeks gestation)
• Congenital heart disease
• Chronic lung disease
• Dosing: 15 mg/kg IM monthly for 5 doses, typically starting November/December 1

Note: Newer RSV prevention therapies and maternal immunizations are now available 6, though not specifically addressed in the older AAP guidelines reviewed here.